Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy Is First Therapy Approved by European Commission for First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer With Activating Egfr Exon 20 Insertion Mutations
Rybrevant®▼ (Amivantamab)結合化療被歐洲委員會首次批准，用於治療具有EGFR外顯子20插入突變的晚期非小細胞肺癌患者的一線治療。